Scientific Advisory Board

Scientific Advisory Board

The Max Planck Institute is regularly scientifically evaluated in order to ensure the high quality and productivity of its work in the long term. A core component of this evaluation is the independent advisory board, 90% of whose members come from other research institutes, and over half of them are from abroad. The advisory board evaluates the work of the Max Planck Institute every two years. Its members are appointed by the president of the Max Planck Society.

The ongoing evaluation of the institute by the advisory board is complemented by further processes. In particular, this includes the appointment of new scientific members and directors to the Max Planck Institute, as well as the success of the institute in acquiring third party funds and the evaluation of their subprojects in special research areas with neighboring universities.

Name
Facility
Prof. Dr. Shaun Coughlin
Novartis Institutes for Biomedical Research
Cambridge (MA), USA
Prof. Dr. Britta Engelhardt
Medizinische Fakultät
Universität Bern
Bern, Schweiz
Prof. Dr. Axel Haverich
Klinik für Herz-, Thorax-, Transplantations- und Gefäßchirurgie
Medizinische Hochschule Hannover
Hannover, Deutschland
Prof. Dr. Nick Morell
Cambridge Cardiovascular
University of Cambridge, Addenbrooke’s Hospital
Cambridge, UK
Prof. Dr. Alessandra Moretti
Klinikum rechts der Isar - Technical University Munich Department of Medicine I, München
Prof. Dr. Tatiana Petrova
Department of Oncology
University of Lausanne
Epalinges, Schweiz
Prof. Dr. Frédéric Relaix
Institut Mondor de Recherche Biomédicale
Université Paris-Est Créteil Val de Marne
Creteil, Frankreich
Lila Solnica-Krezel, PhD
Washington University School of Medicine in St. Louis, Department of Developmental Biology, ST. LOUIS, MO 63110, USA
Prof. Dr. Uwe Strähle
Institute of Toxicology and Genetics
Karlsruhe Institute of Technology
Eggenstein-Leopoldshafen, Germany
Prof. Dr. Stephen J. Tapscott
Fred Hutchinson Cancer Research Center
Seattle, USA
Go to Editor View